JHVEPhoto/iStock Editorial via Getty Images Article Thesis Broadcom Inc. ( AVGO ) reported its most recent earnings results on Wednesday afternoon, easily outperforming expectations. The company is showing a strong and improving growth rate, its near-term outlook is quite positive, and the valuation has come down recently. For investors looking for AI exposure, Broadcom could be attractive at curr...
JHVEPhoto/iStock Editorial via Getty Images Article Thesis Broadcom Inc. ( AVGO ) reported its most recent earnings results on Wednesday afternoon, easily outperforming expectations. The company is showing a strong and improving growth rate, its near-term outlook is quite positive, and the valuation has come down recently. For investors looking for AI exposure, Broadcom could be attractive at current prices, I believe. Past Coverage Of Broadcom I have written about Broadcom here on Seeking Alpha in the past, most recently in December, three months ago, when I published this article , in which I gave Broadcom a neutral rating, noting both its appealing growth and its rather high valuation at the time. Since then, shares have pulled back, while growth has accelerated further, which is why I am more bullish today. With Broadcom having announced its most recent quarterly earnings results on Wednesday, it's time for a thesis update on the company. Broadcom Q1 Earnings: What Happened? Broadcom Inc. announced its Q1 results on Wednesday, following the market's close. These were the headline numbers from the company's earnings report: Broadcom Inc. Q1 Earnings Results (Seeking Alpha) We see that Broadcom delivered a double beat, which is, of course, the ideal outcome—the company's actual performance was better compared to what Wall Street analysts were estimating for both business growth and profitability. The beats weren't overly large, at ~1% to 2%, but it was a double beat nevertheless—the fifth one in a row. At the time of writing, shares are up by a couple of percentage points in after-hours trading, although this could change throughout Thursday as more and more investors digest Broadcom's earnings report and Q2 guidance. Broadcom: Accelerating Growth Delving into the Q1 report, let's start with Broadcom's business growth rate: Revenues were 29% higher than one year earlier, which is a pretty strong growth rate all by itself, but which also represents the continuation...
JHVEPhoto/iStock Editorial via Getty Images Article Thesis Broadcom Inc. ( AVGO ) reported its most recent earnings results on Wednesday afternoon, easily outperforming expectations. The company is showing a strong and improving growth rate, its near-term outlook is quite positive, and the valuation has come down recently. For investors looking for AI exposure, Broadcom could be attractive at curr...
JHVEPhoto/iStock Editorial via Getty Images Article Thesis Broadcom Inc. ( AVGO ) reported its most recent earnings results on Wednesday afternoon, easily outperforming expectations. The company is showing a strong and improving growth rate, its near-term outlook is quite positive, and the valuation has come down recently. For investors looking for AI exposure, Broadcom could be attractive at current prices, I believe. Past Coverage Of Broadcom I have written about Broadcom here on Seeking Alpha in the past, most recently in December, three months ago, when I published this article , in which I gave Broadcom a neutral rating, noting both its appealing growth and its rather high valuation at the time. Since then, shares have pulled back, while growth has accelerated further, which is why I am more bullish today. With Broadcom having announced its most recent quarterly earnings results on Wednesday, it's time for a thesis update on the company. Broadcom Q1 Earnings: What Happened? Broadcom Inc. announced its Q1 results on Wednesday, following the market's close. These were the headline numbers from the company's earnings report: Broadcom Inc. Q1 Earnings Results (Seeking Alpha) We see that Broadcom delivered a double beat, which is, of course, the ideal outcome—the company's actual performance was better compared to what Wall Street analysts were estimating for both business growth and profitability. The beats weren't overly large, at ~1% to 2%, but it was a double beat nevertheless—the fifth one in a row. At the time of writing, shares are up by a couple of percentage points in after-hours trading, although this could change throughout Thursday as more and more investors digest Broadcom's earnings report and Q2 guidance. Broadcom: Accelerating Growth Delving into the Q1 report, let's start with Broadcom's business growth rate: Revenues were 29% higher than one year earlier, which is a pretty strong growth rate all by itself, but which also represents the continuation...
Micron Technology (NASDAQ: MU) traded at $400.77 Thursday morning, bouncing 5.55% off the prior close after an 8.46% one-month pullback tied to geopolitical-driven semiconductor selling. The 12-month run has been extraordinary: +340.89% from $90.90 a year ago. The question investors are asking is whether this dip is a gift or a warning. The 24/7 Wall ... Micron Stock Price Prediction: Where Will M...
Micron Technology (NASDAQ: MU) traded at $400.77 Thursday morning, bouncing 5.55% off the prior close after an 8.46% one-month pullback tied to geopolitical-driven semiconductor selling. The 12-month run has been extraordinary: +340.89% from $90.90 a year ago. The question investors are asking is whether this dip is a gift or a warning. The 24/7 Wall ... Micron Stock Price Prediction: Where Will MU Be in 1 Year?
Quick Read Micron (MU) is at $400.77, up 5.55% after Q1 revenue of $13.64B and EPS of $4.78 beat estimates. Q2 guidance: $18.70B revenue, $8.42 EPS. Wall St. target is $316.13, bull case $479.55. Micron’s sold-out HBM capacity through 2026 as the only American HBM supplier and new AI infrastructure products with Nvidia drove exceptional Q1 results and strong Q2 guidance. The analyst who called NVI...
Quick Read Micron (MU) is at $400.77, up 5.55% after Q1 revenue of $13.64B and EPS of $4.78 beat estimates. Q2 guidance: $18.70B revenue, $8.42 EPS. Wall St. target is $316.13, bull case $479.55. Micron’s sold-out HBM capacity through 2026 as the only American HBM supplier and new AI infrastructure products with Nvidia drove exceptional Q1 results and strong Q2 guidance. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE. Micron Technology (NASDAQ: MU) traded at $400.77 Thursday morning, bouncing 5.55% off the prior close after an 8.46% one-month pullback tied to geopolitical-driven semiconductor selling. The 12-month run has been extraordinary: +340.89% from $90.90 a year ago. The question investors are asking is whether this dip is a gift or a warning. The 24/7 Wall St. Price Target Summary Metric Value Current Price $400.77 24/7 Wall St. Price Target $316.13 Upside/Downside −21.12% Confidence Level 90% Our $316.13 price target sits below the current price, reflecting valuation stretch. The fundamental story remains compelling, so consider this target one datapoint among many. A Note Before We Begin Our $316.13 target is below where Micron trades today. Two catalysts could prove our model too conservative: HBM capacity is sold out for all of 2026, and the company is the only American HBM supplier. We've included a full bull case below. READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks A Rally Built on Real Earnings Micron's fiscal Q1 2026 results, reported December 17, 2025, were exceptional. Revenue came in at $13.64 billion, beating estimates by 5.91% and growing 56.65% year over year. Non-GAAP EPS of $4.78 exceeded the $3.9397 estimate by 21.33%. GAAP gross margin expanded from 38.4% a year ago to 56.0%, and free cash flow hit a company record of $3.91 billion. The stock has climbed from $243.64 at the time of that filing to $400.77, a move that prices in significant forward execution. How We Buil...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Getty Images Good morning! Here's the latest in trending: Job cuts: Morgan Stanley ( MS ) will lay off 3% of its workforce , while Amazon ( AMZN ) is cutting a "small number" of jobs in its robotics division . Resolving dispute: Anthropic ( ANTHRO ) is back in talks with ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Getty Images Good morning! Here's the latest in trending: Job cuts: Morgan Stanley ( MS ) will lay off 3% of its workforce , while Amazon ( AMZN ) is cutting a "small number" of jobs in its robotics division . Resolving dispute: Anthropic ( ANTHRO ) is back in talks with the Pentagon, while its investors and Big Tech raise concerns over its "supply-chain risk" label. Time for refunds: A federal judge ordered the Trump administration to issue refunds after recalculating the duties importers paid and excluding IEEPA tariffs . Ripple effect The U.S.-Israel-Iran war is not just impacting energy markets . A South Korean lawmaker just warned that the fallout could disrupt the supply of key chipmaking materials and push electricity costs higher. What's at stake: "The semiconductor industry expressed concerns that rising oil prices could lead to higher electricity costs domestically, which could ultimately undermine the price competitiveness of semiconductors," lawmaker Kim Young-bae said after meeting with executives from companies such as Samsung Electronics ( SSNLF ) and SK Hynix ( HXSC.F ). Kim said South Korean companies source key chipmaking materials from the Middle East, like helium, and any supply disruption will impact chip production. "Logistics and transportation expenses will likely be the biggest issues rising from the situation in the Middle East," he said. Gulf dependence: South Korea is "highly dependent" on the Middle East for 14 items used in chipmaking, including helium, bromine and chip inspection equipment, its industry ministry said. Some of these can be sourced domestically or from other countries. But 54% of its naphtha imports travel through the Strait of Hormuz, and supplies could be hit if the Iran conflict is prolonged. South Korea sources 70% of its oil from the Middle East. The government said it has enough oil reserv...
Mobile tech conference Mobile World Congress is underway in Barcelona, where Qualcomm (QCOM) outlined its artificial intelligence (AI) strategy and upcoming innovations, including bringing 6G to market by 2029. Qualcomm CFO and COO Akash Palkhiwala speaks with Market Catalysts host Julie Hyman about the company's 6G plans and how they will transform the consumer electronics landscape. To watch mor...
Mobile tech conference Mobile World Congress is underway in Barcelona, where Qualcomm (QCOM) outlined its artificial intelligence (AI) strategy and upcoming innovations, including bringing 6G to market by 2029. Qualcomm CFO and COO Akash Palkhiwala speaks with Market Catalysts host Julie Hyman about the company's 6G plans and how they will transform the consumer electronics landscape. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
US equity markets were tracking in the red before the opening bell Thursday as investor concerns per Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles.
US equity markets were tracking in the red before the opening bell Thursday as investor concerns per Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles.
A headline-grabbing stunt for Evita, which saw her perform on the outdoor balcony every night, drew huge crowds to the concourse outside the Palladium, sparking a debate about whether it was fair to the ticket buyers sitting inside the theatre.
A headline-grabbing stunt for Evita, which saw her perform on the outdoor balcony every night, drew huge crowds to the concourse outside the Palladium, sparking a debate about whether it was fair to the ticket buyers sitting inside the theatre.
China’s “ two sessions ” this year presents less of a story of an economic miracle than of transition: from high-speed to high-quality growth, and from dependence on external demand to a more resilient, innovation-driven economy. Against a backdrop of global tensions and fragmenting supply chains, Beijing is using this political moment to signal that it sees opportunity in adversity and is prepare...
China’s “ two sessions ” this year presents less of a story of an economic miracle than of transition: from high-speed to high-quality growth, and from dependence on external demand to a more resilient, innovation-driven economy. Against a backdrop of global tensions and fragmenting supply chains, Beijing is using this political moment to signal that it sees opportunity in adversity and is prepared to recalibrate its development model rather than cling to the habits of the boom years. For China, the key question is no longer whether it can hit a headline growth number for a single year, but whether it can reshape the foundations of its economy in a way that is robust to shocks from geopolitics, demographics, finance and climate. Premier Li Qiang’s government work report on Thursday offers a window into how the leadership intends to answer that question. What emerges is a cautiously optimistic vision of slower, steadier growth powered more by chips, data and domestic demand. Advertisement The 2026 growth target of 4.5 to 5 per cent is not an admission of weakness; it is a marker of economic maturity. Moving away from “growth at all costs” suggests a greater focus on better allocation of capital, improved environmental outcomes and more attention to financial stability. One of the most encouraging aspects of this year’s agenda is the continued emphasis on innovation and technological upgrading as central pillars of China’s long-term strategy. The subtext is clear: the days when China could grow by simply adding more labour and capital to low-tech factories are over. Future gains will come from doing more with less and doing it at the frontier. Advertisement In practice, this means elevating research and development (R&D) from a supporting role to centre stage. Increased R&D spending, greater emphasis on basic science and support for strategic sectors are all part of the package.
Laurene Powell Jobs attends the Clinton Global Initiative 2024 Annual Meeting at New York Hilton Midtown on September 24, 2024 in New York City. John Nacion | Getty Images A version of this article first appeared in CNBC's Inside Wealth newsletter with Robert Frank, a weekly guide to the high net worth investor and consumer. Sign up to receive future editions, straight to your inbox. Fears of an a...
Laurene Powell Jobs attends the Clinton Global Initiative 2024 Annual Meeting at New York Hilton Midtown on September 24, 2024 in New York City. John Nacion | Getty Images A version of this article first appeared in CNBC's Inside Wealth newsletter with Robert Frank, a weekly guide to the high net worth investor and consumer. Sign up to receive future editions, straight to your inbox. Fears of an artificial intelligence bubble roiled the stock market in February, but investment firms of ultra-wealthy families still made bullish bets on high-flying AI startups. For instance, Laurene Powell Jobs' investment and philanthropy firm Emerson Collective joined a $1 billion fundraise for AI developer World Labs last month. World Labs' first product, Marble, allows users to create and edit 3D world models with text and image prompts. And Indian billionaire Azim Premji's namesake family office also participated in a $315 million Series E round for Runway, an AI video generation startup. In February, family offices made 41 direct investments in companies, nearly all associated with AI, according to data provided exclusively to CNBC by private wealth platform Fintrx. World Labs and Runway are in good company. AI-related startups raised $171 billion in February, pushing the month's total startup funding from all investors to a record $189 billion, according to Crunchbase data . Rounds by Anthropic , OpenAI and Waymo drew the lion's share of the funds, while four other companies, including World Labs, garnered ten-figure rounds. In other family office deals, Hillspire, the firm of ex-Google CEO Eric Schmidt and his wife, Wendy, invested in a novel startup that could benefit the rest of its AI portfolio. Last month, the firm joined a $150 million Series B for Goodfire, which aims to understand how AI models work in order to improve them. Schmidt warned at a conference in October that AI models are susceptible to hacking for malicious purposes. However, he said he is generally optimi...
aristotoo/iStock via Getty Images Introduction This year, so far, has been quite something. While I'm writing this, the S&P 500 is basically flat on the year. That’s not a bad thing if we consider that the index returned 16% last year. In 2024, it returned 23%. In the year before that, it returned 24%. Also, there's the war in Iran. So yes, if you had any meaningful index exposure or a portfolio w...
aristotoo/iStock via Getty Images Introduction This year, so far, has been quite something. While I'm writing this, the S&P 500 is basically flat on the year. That’s not a bad thing if we consider that the index returned 16% last year. In 2024, it returned 23%. In the year before that, it returned 24%. Also, there's the war in Iran. So yes, if you had any meaningful index exposure or a portfolio with a high correlation to the market, odds are you made a lot of money in the past. Taking a break after such a blowout performance is only normal, as we have had just one period since the 1980s that saw more than three consecutive strong years. That was ahead of the dot-com bubble, as seen in the chart below from JPMorgan. Think about that. JPMorgan The thing, however, is that this performance wasn’t evenly distributed. And to be honest, it never is. Since 2015, this has been a very tech-led market, which has concentrated tremendous wealth in that area. As I have often written, Nvidia ( NVDA ) alone is worth more than the five smallest S&P 500 sectors combined. That doesn’t mean Nvidia deserves to be sold, yet it shows how much capital in absolute terms is concentrated in some areas. Now, some of that has started to unwind, and it has happened extremely violently. As we can see below, year-to-date, energy is up 25%, followed by materials, consumer staples, and industrials. Three of these sectors are cyclical. Consumer staples are likely among the winners due to their ability to withstand AI disruption. Although I agree with people who make the case that it may be weird to sell a stock like Amazon ( AMZN ) to buy PepsiCo ( PEP ), which now has a higher P/E multiple than Amazon, as I have written in the past, I think it’s a different story due to a lot of capital rushing into safety. State Street And, to get back to my main point, because there is so much capital in certain areas, even a slight rotation can have a violent impact on smaller sectors and stocks. That’s what we ...
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected to be reported in April. Based on previously reported responses in patients with triple-negative brea...
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected to be reported in April. Based on previously reported responses in patients with triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) in the Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), expansion cohorts are now open and enrolling patients with these tumor types; based on an additional response in a patient with Hodgkin lymphoma, a further expansion cohort of patients with Hodgkin lymphoma will begin shortly. The IND application for CTX-10726 (PD-1 x VEGF-A bispecific antibody) received FDA clearance and the Phase 1 study will be open for enrollment in Q1. Bing Gong, PhD has been promoted to Chief Scientific Officer. Dr. Gong joined Compass in 2015 and has been instrumental in the expansion and advancement of the Compass discovery and development pipeline. $209 million in cash and marketable securities at year end 2025, which is expected to fund operations into 2028. BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2025 financial results and provided a business update. “2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the primary endpoint of overall response rate in the COMPANION-002 Phase 2/3 study in patients with biliary tract cancer. We are excited to report the results of the key secondary endpoints next month,” said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors. “The upcoming tovecimig PFS/OS data release could be t...
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therap...
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed $91.2 million of net revenue in the quarter. For the full-year 2025, CorMedix achieved total revenue of $311.7 million and pro forma total revenue of $401.3 million. (1) In the fourth quarter of 2025, the Company recognized Net Income of $14.0 million and adjusted EBITDA of $77.2 million. (2) Basic and Fully Diluted EPS were $0.18 and $0.16 per share, respectively. Basic and Fully Diluted EPS were $0.18 and $0.16 per share, respectively. CorMedix reiterates previously established guidance for 2026, including net revenue of between $300 and $320 million and adjusted EBITDA of between $100 and $125 million. CorMedix announced in early February that its Board of Directors approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company’s outstanding common stock. As highlighted during the Company’s recent Analyst Day, CorMedix expects clinical data from the Phase 3 ReSPECT study of REZZAYO® (rezafungin for injection) in the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplant in Q2 2026. In addition, the ongoing Phase 3 study of taurolidine/heparin catheter...
Anthropic In Chaos: CEO Tries To Salvage Pentagon Contract After Slamming Trump, Altman In Leaked Letter Things over at Anthropic are getting wild. On Friday, the Trump administration 'fired' the woke serial copyright infringer , industry disruptor and software-engineer-extinctor after a bruising dispute with the Pentagon came to a head over ethical concerns surrounding Claude's military use - spe...
Anthropic In Chaos: CEO Tries To Salvage Pentagon Contract After Slamming Trump, Altman In Leaked Letter Things over at Anthropic are getting wild. On Friday, the Trump administration 'fired' the woke serial copyright infringer , industry disruptor and software-engineer-extinctor after a bruising dispute with the Pentagon came to a head over ethical concerns surrounding Claude's military use - specifically, domestic surveillance and fully autonomous weapons. The Pentagon demanded to use ClaudeAI for "any lawful purpose" with no guardrails - or having to ask permission from a bunch of blue-haired Karens in a life-or-death scenario. The chatbot's supposedly idealistic leader (whose sister and Anthropic co-founder, Daniella Amodei, is married to Holden Karnofsky, the founder of Effective Altruism himself ) had to signal virtuemaxx to his employees, and said no. OpenAi's Sam Altman, who is a different kinds of opportunistic sociopath with zero moral qualms, pretended to side with Amodei at first only to immediately swoop in and poach Anthropic's Pentagon contract. Meanwhile, Amodei's investors, who had just dumped all their cocaine cash for the next 20 years into his company at a $380 billion valuation, and realized they would never see their money again if the government blacklisted and banned the company from all government supply chains, were terribly vexxed. The spat resulted in three things; first, in addition to getting 'fired,' Anthropic was deemed a "supply-chain risk" (making them radioactive to the defense industry) - and federal agencies were given six months to ditch Anthropic products. Second, OpenAI's Sam Altman slid into Hegseth's DMs (through proper channels, we're sure) and landed Anthropic's contract - which they revised to beef up and clarify safety protocols, and third, Anthropic CEO Dario Amodei threw a ripper of a tantrum in a leaked memo sent to over 2,000 employees attacking the Trump administration and OpenAI. For Silicon Valley investors and al...
T20 World Cup updates from Mumbai; 1.30pm GMT start Sign up for the Spin | Follow us on Bluesky | Mail Tim Afternoon everyone and welcome to the biggest thing since the Ashes. After a largely wretched winter, England have somehow made their way to a World Cup semi-final. They are now David, up against Goliath: the world’s best T20 team, on their home turf. But India have looked vulnerable at times...
T20 World Cup updates from Mumbai; 1.30pm GMT start Sign up for the Spin | Follow us on Bluesky | Mail Tim Afternoon everyone and welcome to the biggest thing since the Ashes. After a largely wretched winter, England have somehow made their way to a World Cup semi-final. They are now David, up against Goliath: the world’s best T20 team, on their home turf. But India have looked vulnerable at times in this tournament and England have kept finding a way to win, mostly by luring the opposition into a false sense of security and then relying on Will Jacks to bail them out. Being the underdogs should suit them nicely. It’s the third time in a row that these two sides have met in the semi-final of a T20 World Cup. England won the first with the greatest of ease before India took all too predictable revenge in the second. This one is harder to call. India bring more firepower, especially now that Sanju Samson has come to the party. They have Jasprit Bumrah, the world’s most lethal fast bowler, and spinners to spare. Continue reading...
TSLA Stock is moving on the confirmation of Samsung Electronics that its Taylor, Texas, semiconductor factory will only reach true mass production in 2027. Meanwhile, Tesla, Inc. (TSLA) closed at $405.94, gaining $13.51 or 3.44% at 4:00 PM EST. This delay disrupts Tesla’s plan to utilize advanced 2nm chips for its AI5 and AI6 platforms, as the 2027 timeline lags behind the automaker’s hardware roa...
TSLA Stock is moving on the confirmation of Samsung Electronics that its Taylor, Texas, semiconductor factory will only reach true mass production in 2027. Meanwhile, Tesla, Inc. (TSLA) closed at $405.94, gaining $13.51 or 3.44% at 4:00 PM EST. This delay disrupts Tesla’s plan to utilize advanced 2nm chips for its AI5 and AI6 platforms, as the 2027 timeline lags behind the automaker’s hardware roadmap. In April, Samsung mentioned that it focused on commencing 2-nanometer mass semiconductor production in its fabrication business and gained key orders for the next-generation technology. Tesla-Samsung Contract Timeline Extended The mass production of semiconductor chips at the Taylor fab has been slowed down once more. Although the plant has initiated confined pilot operations, full-scale production is still undetermined, according to multiple sources cited by Korea JoongAng Daily. The schedule has continued to be delayed, and it is now anticipated that a full-scale ramp-up for meaningful production volumes could be pushed to early next year, according to a source familiar with developments, the publication was told. According to the X (formerly Twitter) post by Elon Musk, CEO of Tesla, Samsung Electronics has signed a long-term contract valued at approximately $17 billion for supplying semiconductor chips to Tesla, as confirmed in a regulatory filing by Tesla and the South Korean Organization. Samsung’s giant new Texas fab will be dedicated to making Tesla’s next-generation AI6 chip. The strategic importance of this is hard to overstate. Samsung currently makes AI4. TSMC will make AI5, which just finished design, initially in Taiwan and then Arizona. — Elon Musk (@elonmusk) July 28, 2025 A memory chipmaker disclosed in a regulatory filing that it has a long-term contract with an unnamed firm. According to the agreement, the effective start date of the contract is July 26, 2026, which is also when the chipmaker will begin receiving orders, and the contract is set to op...
pamspix/iStock via Getty Images Fund performance The portfolio returned 2.06% over the quarter on a net asset value basis, lagging the ASX 200's 7.33% return. The gap was driven primarily by stock-specific weakness in healthcare and consumer discretionary, along with our materials positioning. This was mitigated by positive contributions from industrials and communication services, where stock sel...
pamspix/iStock via Getty Images Fund performance The portfolio returned 2.06% over the quarter on a net asset value basis, lagging the ASX 200's 7.33% return. The gap was driven primarily by stock-specific weakness in healthcare and consumer discretionary, along with our materials positioning. This was mitigated by positive contributions from industrials and communication services, where stock selection remained firm. 1 Looking closer at the key drivers of performance, healthcare was the largest detractor. Pro Medicus's ( PMCUF ) share price weakened on softer order flows, with ResMed ( RMD ) and Cochlear ( CHEOF ) also weighing on results. Across the sector, sentiment remained fragile as investors reassessed growth expectations and regulatory uncertainty persisted. Another key detractor was weakness in some of our consumer discretionary holdings, notably Aristocrat Leisure ( ARLUF ), which was weighed down by weakening gaming trends, and JB Hi-Fi, which suffered from subdued consumer spending. Materials also lagged despite strong commodity prices, as the lack of exposure to Evolution Mining ( CAHPF ), South32 ( SOUHY ) and Newmont Corporation ( NEM ) detracted from performance. This was partially offset by our holdings in Northern Star ( NESRF ), Rio Tinto ( RIO ) and Capstone Copper ( CSCCF ), which all posted solid gains. Another key stock detractor was Xero (ZROLF), the biggest individual detractor in the portfolio, as its revenues increased healthily, but profit growth lagged expectations. Higher spending on product development and US expansion weighed on margins and near-term profitability. Investors grew concerned about rising costs and slower margin improvement, despite solid subscriber growth and high customer retention. Cumulative and annualized total return as of January 31, 2026 (%) NAV Market Price ASX 200 Net Index 10 Years (p.a.) 9.75 10.62 9.74 5 Years (p.a.) 7.82 9.02 7.99 3 Years (p.a.) 7.92 9.44 9.37 1 Year 12.38 19.57 20.35 Year to date 4.06 8.13...
filmestria Aptiv ( APTV ) priced an upsized private offering of $1.6B in senior notes, including $800M in 6.125% senior notes due in 2031 and $800M in 6.375% senior notes due in 2034. The offering is upsized by $100M from the initial $1.5B size. The offering is expected to close on March 18, 2026. The net proceeds, plus term loan borrowings, will fund a dividend to Aptiv, leaving Versigent with $4...
filmestria Aptiv ( APTV ) priced an upsized private offering of $1.6B in senior notes, including $800M in 6.125% senior notes due in 2031 and $800M in 6.375% senior notes due in 2034. The offering is upsized by $100M from the initial $1.5B size. The offering is expected to close on March 18, 2026. The net proceeds, plus term loan borrowings, will fund a dividend to Aptiv, leaving Versigent with $400M cash for general purposes post-spin-off and fees. The proceeds of the offering will be deposited into escrow for the holders of the notes. More on Aptiv Aptiv PLC (APTV) Presents at Barclays 43rd Annual Industrial Select Conference Transcript Aptiv PLC (APTV) Q4 2025 Earnings Call Transcript Aptiv PLC 2025 Q4 - Results - Earnings Call Presentation Aptiv forecasts $30B+ in 2026 bookings with Versigent spin while navigating FX and commodity headwinds Aptiv slips as weak Q1 profit guidance, margin pressure offsets Q4 beat